Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
about
Structured treatment interruptions (STI) in chronic suppressed HIV infection in adultsModelling the impact of antiretroviral use in resource-poor settingsComparative Analysis of Nearly Full-Length Hepatitis C Virus Quasispecies from Patients Experiencing Viral Breakthrough during Antiviral Therapy: Clustered Mutations in Three Functional Genes, E2, NS2, and NS5aSimple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutationsFactors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infectionHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanCombining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations.Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsReappearance of an 11-year-old sequence in an HIV-1 infected patient during treatment interruption.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status.Minority variants of drug-resistant HIV.In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.Evolution of drug-resistant viral populations during interruption of antiretroviral therapyInfectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infectionAccurate sampling and deep sequencing of the HIV-1 protease gene using a Primer IDDo Taq-generated RT-PCR products from RNA viruses accurately reflect viral genetic heterogeneity?HIV-1 dynamics in vivo: implications for therapy.Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistanceOptimization of allele-specific PCR using patient-specific HIV consensus sequences for primer designColinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencingRole of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.Female genital tract shedding of CXCR4-tropic HIV Type 1 is associated with a majority population of CXCR4-tropic HIV Type 1 in blood and declining CD4(+) cell counts.Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adultsEmergence of an HIV-1 cluster harbouring the major protease L90M mutation among treatment-naïve patients in Tel Aviv, Israel.Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay.Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assayUse of a locked-nucleic-acid oligomer in the clamped-probe assay for detection of a minority Pfcrt K76T mutant population of Plasmodium falciparum.Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.Human immunodeficiency virus genotype and hypertriglyceridemia.Detection of drug-resistant HIV minorities in clinical specimens and therapy failure.
P2860
Q24245709-5BAAD94F-484D-4843-B589-6E9EF802F09AQ25255753-032A83DF-F2FE-4049-8CA9-9CE907BF641EQ27486924-C56027FF-D951-419C-BAB0-303C9AB16F48Q28469253-BA404045-CF84-49B4-B39E-AE7E2AA7D997Q28477780-14E68A82-06B5-4FAF-ABFA-20473F8636F0Q28478934-B3C55E17-0CEB-4B9B-B35F-97ACD0DFF244Q28537608-162475BB-333A-4775-8300-DBE0E296E8C4Q31107886-9A182608-031A-4FAC-A2FB-FF185C6564D5Q33299456-0768CE37-55B0-4071-A308-800ECED7D14EQ33302143-4B0ED2EC-77C8-446B-BEDF-95BA2AEA22A7Q33592278-7EC25C01-29B7-4703-A983-BA40278A9C30Q33714377-43C56EFD-E3EE-4F41-8BD1-11E0565F103CQ33908859-B33A92C2-64C0-4571-B3E8-68DA6026845DQ34047780-72B5F4B5-173C-4382-9B20-3D045B3AE5B6Q34529347-29FB53E4-35A4-44CF-BD5E-9D7FD5EE4F91Q34719734-AD835C3F-AF66-49F9-BEFC-05FC28098F19Q35077423-5991E9FB-859B-4201-B0C1-BCDCDB23D2FEQ35104695-531D5B7F-8ABC-4033-81EA-D387992799BAQ35647691-2DC02E16-49E8-4675-97B4-EFD992548CEFQ35680444-CCFA5E53-51FD-4885-851C-AF626F4C1ECDQ35701633-318ED4C3-07D1-4781-873D-DEC4E54DA6C9Q35806160-BBC989FE-A519-4661-B699-1B5F5695B31AQ35914785-0541B188-102A-426D-973A-0D1621C372DDQ36525986-5CD1B0E7-8967-4BBA-B169-2B621B7CC4E9Q36950126-C58E1E15-6499-4D4D-800C-AE819219BF85Q37093847-1C1C55EC-452A-4F32-9056-611B60E92636Q37189622-C4724D2A-8EF6-478B-A3A8-5407F7762794Q37483095-CFE8ED10-34B4-4337-B2F0-B085785C2388Q37494332-17D6FE4D-D1F7-40E4-A924-9A8D3348428DQ37582339-82068B7D-330C-4C1B-8C48-09765EE87883Q39038944-73F803CE-829B-4CF3-8C9C-1CB32AC1ABACQ39685276-29588EF1-75A6-4ADD-A0B9-7E2ED21FAE38Q39685954-65E697A3-246E-4D84-B117-3A79FD231877Q39989338-BB2A9AD3-12CA-4CAA-930B-1CB3AF21E982Q40909665-FBD3A843-7B21-41FA-9654-F6A4FD536AFBQ41912021-252D5091-6213-46AD-BBA3-CE2E9F4747C9Q42929822-BE7153DD-D1F2-4B82-8F0B-21AFB9CB5EBDQ42931192-D42F7336-6B70-4A35-899D-E1301199F2A9Q44060430-6D7859A7-90D2-42CB-98A4-A562181EAFA0Q44750837-CDFAF74C-3A0E-4E74-9BAB-0C279C971D9E
P2860
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Changes in human immunodeficie ...... ailing antiretroviral therapy.
@en
type
label
Changes in human immunodeficie ...... ailing antiretroviral therapy.
@en
prefLabel
Changes in human immunodeficie ...... ailing antiretroviral therapy.
@en
P2093
P2860
P1433
P1476
Changes in human immunodeficie ...... failing antiretroviral therapy
@en
P2093
Brun-Vézinet F
Descamps D
Lecossier D
P2860
P304
P356
10.1128/JVI.75.14.6410-6417.2001
P577
2001-07-01T00:00:00Z